2.71
Inmune Bio Inc stock is traded at $2.71, with a volume of 1.02M.
It is down -2.52% in the last 24 hours and down -63.23% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$2.78
Open:
$2.77
24h Volume:
1.02M
Relative Volume:
0.42
Market Cap:
$63.92M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.6228
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+11.98%
1M Performance:
-63.23%
6M Performance:
-67.97%
1Y Performance:
-68.00%
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INMB
Inmune Bio Inc
|
2.71 | 75.73M | 155.00K | -30.01M | -11.98M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
Oct-21-24 | Initiated | Alliance Global Partners | Buy |
Sep-27-24 | Initiated | Raymond James | Outperform |
Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
Jun-01-23 | Initiated | Robert W. Baird | Outperform |
May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Jul-07-21 | Reiterated | Maxim Group | Buy |
Apr-21-21 | Initiated | B. Riley Securities | Buy |
Jan-22-21 | Reiterated | Maxim Group | Buy |
Sep-01-20 | Initiated | BTIG Research | Buy |
Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
How does INmune Bio Inc. generate profit in a changing economyDynamic growth stocks - jammulinksnews.com
Why INmune Bio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Metal.it
Inmune Bio Reveals Promising XPro™ Trial Results - TipRanks
What analysts say about INmune Bio Inc. stockConsistently high returns - PrintWeekIndia
Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at - GuruFocus
INmune Bio Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met - TipRanks
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times
INmune Bio to present additional Phase 2 Alzheimer’s trial data By Investing.com - Investing.com Canada
Is INMB more suitable for short-term or long-term investment? - AInvest
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com
Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser
What makes INmune Bio Inc. stock price move sharplyFree Investment Group - beatles.ru
How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser
Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN
INmune Bio reverses early gains after stock offering - MSN
INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN
INmune Bio - The Pharma Letter
XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest
INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
(INMB) Proactive Strategies - news.stocktradersdaily.com
INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener
INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize
INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus
A Drug-Trial Stock Sale - Bloomberg
INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmune Bio Inc Stock (INMB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):